Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000897423-25-000023
Filing Date
2025-02-13
Accepted
2025-02-13 11:38:04
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 19974
2 ITEM 8 EXHIBIT item8exhibit.pdf EX-99 34026
  Complete submission text file 0000897423-25-000023.txt   68541
Mailing Address 201 MAIN STREET SUITE 2100 FORT WORTH TX 76102
Business Address
BRATTON DOUGLAS K (Filed by) CIK: 0001281933 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Subject) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90885 | Film No.: 25618344
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)